Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InsmedMIL:1INSM 45 EPS without NRI is €-4.47 as of Mar. 2026. GuruFocus rates MIL:1INSM with a GF Score™ of 45/100 and a GF Value™ of €163.31 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,165 Biotechnology companies, Insmed ranks worse than 81.63% on this metric.
Insmed's earnings per share without non-recurring items for the
three
months ended in Mar. 2026 was €-0.80.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was €-4.47.
During the past 3 years, the average earnings per share (NRI) Growth Rate was -10.80% per year.
During the past 5 years, the average earnings per share (NRI) Growth Rate was -13.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Insmed's EPS without NRI or its related term are showing as below:
MIL:1INSM'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -40.3 Med: -8.75 Max: 52.5
Current: -10.8
During the past 13 years, Insmed's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 52.50% per year. The lowest was -40.30% per year. And the median was -8.75% per year.
MIL:1INSM's 3-Year EPS without NRI Growth Rate is ranked worse than 81.63% of 1165
companies
in the Biotechnology industry
Industry Median: 16.2
vs MIL:1INSM: -10.80
Insmed's EPS (Diluted) for the
three
months ended in Mar. 2026 was €-0.66.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €-4.94.
Insmed's EPS (Basic) for the
three
months ended in Mar. 2026 was €-0.66.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was €-4.94.
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Insmed EPS without NRI Related Terms
Insmed EPS without NRI Historical Data
* Premium members only.
The historical data trend for Insmed's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIL:1INSM vs INCY, BNTX, MRNA: EPS without NRI Comparison
For the Biotechnology subindustry, Insmed's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Insmed PE Ratio without NRI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Insmed's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Insmed's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-4.47
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Insmed (MIL:1INSM) has a EPS without NRI of €-4.47 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Insmed and its competitors. According to the industry distribution chart, Insmed ranks #951 out of 1165 companies in the Biotechnology industry, placing it in the top 81.6%.
Is Insmed's EPS without NRI too high?
Insmed's current EPS without NRI is €-4.47. Based on the distribution chart, Insmed ranks #951 out of 1165 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Insmed has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Insmed's EPS without NRI compare to INCY and BNTX?
According to the Biotechnology industry distribution chart, Insmed ranks #951 out of 1165 companies for EPS without NRI. This places Insmed in the lower half of its industry. The industry median EPS without NRI is 16.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.20, based on 1,165 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Insmed and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Insmed's current EPS without NRI is €-4.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insmed stock overvalued right now?
Based on GuruFocus' analysis, Insmed (MIL:1INSM) is currently considered Possible Value Trap. The stock's GF Value™ is €163.31, compared to a current price of €86.10 — trading 47.3% below its estimated fair value. The current EPS without NRI is €-4.47. Insmed's overall GF Score™ is 45/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Insmed (MIL:1INSM), the current EPS without NRI is €-4.47 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Insmed (MIL:1INSM) Overvalued in 2026?
Based on GuruFocus' analysis, Insmed stock appears to be undervalued.
The current stock price of €86.10 is trading 47.3% below its estimated GF Value™ of €163.31.
GuruFocus considers Insmed to be Possible Value Trap.
Key valuation signals for MIL:1INSM:
EPS without NRI: €-4.47
GF Value™: €163.31 vs. price of €86.10 (47.3% below fair value)
No single metric tells the full story. See the MIL:1INSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
45GF Score
Get the complete analysis for MIL:1INSM
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:1INSM has been successfully added to your 
